UCSF Multiple Sclerosis Center, 675 Nelson Rising Lane, San Francisco, CA 94158, USA.
Palo Alto Medical Foundation, 1501 Trousdale Drive, Burlingame, CA 94010, USA.
Mult Scler Relat Disord. 2018 Feb;20:178-180. doi: 10.1016/j.msard.2018.01.025. Epub 2018 Mar 20.
A 51-year old woman with stage III melanoma participated in a phase II clinical trial in which she received subcutaneous rhGM-CSF injections for 3 years. She was in remission by the end of the trial. Seven months after discontinuing GM-CSF she had her first MS event. The unique timeline of rh-GM-CSF injections in a melanoma trial, during which yearly MRI scans showed subtle stable demyelination followed by RRMS onset shortly after discontinuation of treatment, may provide some insight on the role of GM-CSF in MS.
一位 51 岁的 III 期黑色素瘤女性患者参加了一项 II 期临床试验，她在该试验中接受了为期 3 年的皮下 rhGM-CSF 注射。试验结束时她已缓解。停止 GM-CSF 治疗后 7 个月，她出现了首次 MS 事件。在黑色素瘤试验中 rhGM-CSF 注射的独特时间线，每年 MRI 扫描显示细微的稳定脱髓鞘，随后在治疗停止后不久出现 RRMS 发作，这可能为 GM-CSF 在 MS 中的作用提供了一些见解。
